Keywords: |
immunohistochemistry; cancer chemotherapy; human tissue; treatment outcome; aged; disease course; histopathology; case report; bevacizumab; cisplatin; fluorouracil; advanced cancer; drug withdrawal; liver neoplasms; gemcitabine; pancreatic neoplasms; methodology; antineoplastic agent; radiopharmaceuticals; metastasis; computer assisted tomography; antineoplastic combined chemotherapy protocols; tumor markers, biological; camptothecin; dexamethasone; kidney failure; pathology; cetuximab; tumor marker; cancer therapy; irinotecan; monoclonal antibody; pancreas carcinoma; liver metastasis; chemistry; diagnostic agent; folinic acid; liver tumor; pancreas tumor; fluorodeoxyglucose f 18; computer assisted emission tomography; fluorodeoxyglucose f18; radiopharmaceutical agent; drug derivative; bile duct carcinoma; platinum complex; molecular biology; drug substitution; oxaliplatin; dyspepsia; floxuridine; acinar cell carcinoma; carcinoma, acinar cell; organoplatinum compounds; liver biopsy; leucovorin; therapy; abdominal discomfort; molecularly targeted therapy; molecular targeted therapy; antibodies, monoclonal, humanized; positron-emission tomography and computed tomography; long term survival; acinar cell carcinoma of the pancreas
|